Neuroprotective Effects of (-)-epicatechin on Traumatic Brain Injury Mice by Nuclear Factor E2-related Factor 2 Pathway
Chen Xiangrong,Kou Hongwei,Bao Deming,Sun Xinzhi,Liu Hongjian,Cheng Tian,Wang Yisheng
DOI: https://doi.org/10.3760/cma.j.issn.1001-9030.2019.12.030
2019-01-01
Abstract:Objective To investigate the neuroprotective effect of (-)-epicatechin (EC) on traumatic brain injury (TBI) mice.Methods TBI mouse model was prepared by modified weight drop method.Animals were randomly divided into Sham group,TBI + Veh group and TBI + EC group.At 3 days after TBI,Western blotting was used to detect the expression of Nrf2,SOD1 and NQO1.On days 7 and 28 post TBI,Neurologic deficit score (NDS) and wire hanging test were used to detect the motor function.Tail suspension test and forced swim test were used to evaluate the depressive status of mice after TBI on day 28.Results (1) Compared with Veh group,the expression of Nrf2 in nucles was obviously higher (1.354 ±0.432 vs.0.847 ±0.345) in EC treated group.The expression of SOD1 and NQO1 (1.128 ± 0.326) and (1.325 ± 0.427),P < 0.05) was significantly increased,compared with them in the Veh group [(0.855 ± 0.365) and (1.025 ± 0.317)].NDS showed that EC treatment group on 7 d and 28d scores of motor function [(7.18 ± 1.26) and (3.25 ± 0.91)] significantly improved,compared with the Veh Group [(9.75 ± 1.16) and (6.63 ± 1.06),P < 0.05].In the wire hanging test,the mice in EC group have more latency time (22.48 ±2.26) s and (45.35 ±2.92) s] compared to it in the Veh group [(12.23±2.11) sand (22.53±2.32) s,P<0.05] on day 7 and 28 post TBI.(3) On day 28,in the tail suspension test and force swim test,the immobility time in the EC treated group [(202.88 ± 12.56) and (101.98 ± 22.43)] is shorter than it in the vehicle treated group [(244.48 ± 22.76) and (145.39 ± 19.86),P < 0.05].(4) On day 28 post injury,compared with the Veh group,the lesion volume is smaller in the EC treatd group [(8.95 ± 1.59) mm3 vs.(11.52 ± 1.17) mm3,P <0.01].Conclusion EC protects the brain after TBI by NRf2 pathway.